Peptide Bioavailability: Why Delivery Method Matters and How Subcutaneous, Oral, and Nasal Routes Compare

Bioavailability is one of the most consequential variables in peptide research. A peptide's pharmacological activity depends not only on its binding affinity and mechanism of action but on how much of the administered dose actually reaches systemic circulation in an intact, biologically active form. The delivery route chosen in a study or clinical application shapes absorption kinetics, peak plasma concentrations, and overall exposure, making it a primary consideration in peptide pharmacology.

This overview from the Peptide Register examines published evidence on three major delivery routes: subcutaneous injection, oral administration, and intranasal delivery.

Subcutaneous Injection: The Reference Standard for Peptide Delivery

Subcutaneous injection remains the most common delivery route for peptide therapeutics in clinical use. Subcutaneous injection typically achieves peptide bioavailability in the range of 65% to 100%, depending on the specific molecule and formulation. This high absorption rate occurs because peptides deposited in subcutaneous tissue bypass the gastrointestinal tract entirely, avoiding enzymatic degradation in the stomach and first-pass hepatic metabolism.

Most approved peptide drugs, including insulin, semaglutide (in its injectable form), and octreotide, use subcutaneous delivery. Absorption from subcutaneous tissue occurs primarily through capillary uptake, with larger peptides also entering lymphatic drainage pathways. The absorption rate can vary with injection site, tissue perfusion, and the peptide's molecular weight.

For researchers evaluating peptide study data, subcutaneous bioavailability often serves as the benchmark against which other routes are compared. Understanding how peptides differ from small molecules helps clarify why their delivery challenges are distinct from conventional drugs.

Oral Peptide Delivery: The Challenge of Gastrointestinal Degradation

Oral delivery is the most convenient route for patients, but it presents serious obstacles for peptide molecules. Unmodified peptides administered orally typically show bioavailability below 1% to 2% due to enzymatic degradation and poor membrane permeability. The gastrointestinal tract contains proteases, peptidases, and an acidic gastric environment that rapidly break down most peptide chains before they can reach the intestinal epithelium for absorption.

Oral semaglutide (Rybelsus) represents one of the few commercially successful oral peptide formulations. It uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to protect the peptide and promote transcellular absorption in the stomach. Even with this technology, oral semaglutide achieves a bioavailability of approximately 0.4% to 1%, requiring substantially higher doses than its subcutaneous counterpart to reach comparable plasma levels.

Research into oral peptide delivery continues to explore permeation enhancers, enteric coatings, nanoparticle encapsulation, and enzyme inhibitor co-formulations. However, most of these approaches remain in preclinical or early clinical stages. Oral bioavailability for most unformulated peptides remains negligibly low, a constraint that researchers should account for when reading peptide study designs and interpreting reported outcomes.

Intranasal Delivery: A Middle Ground With Its Own Limitations

Intranasal delivery offers a non-invasive alternative that avoids gastrointestinal degradation. Intranasal peptide delivery generally achieves bioavailability in the range of 1% to 10% for most peptides studied to date. The nasal mucosa provides a relatively thin epithelial barrier with rich vascularity, allowing some peptides to reach systemic circulation without injection.

Several peptide and protein drugs use nasal delivery clinically, including desmopressin (DDAVP) and calcitonin. Desmopressin administered intranasally achieves approximately 3% to 5% bioavailability compared to intravenous delivery. Nasal absorption can be enhanced with mucoadhesive agents, absorption enhancers such as chitosan, and formulation strategies that increase mucosal contact time.

However, the nasal route has practical constraints: limited dose volume (typically under 200 microlitres per nostril), variability introduced by nasal congestion or mucosal condition, and potential for local irritation with repeated use. Peptide molecular weight also matters; molecules above approximately 10 kDa show sharply declining nasal absorption without permeation enhancers.

Emerging Routes and Formulation Research

Beyond these three primary routes, researchers are investigating transdermal delivery using microneedle patches, pulmonary delivery via inhalation, and depot formulations that provide sustained release from a single injection. These approaches remain largely experimental for most peptides, with limited human pharmacokinetic data available. The regulatory pathway for novel peptide delivery systems adds additional complexity, as formulation changes can trigger new approval requirements.

It is worth noting that bioavailability data for many peptides of research interest, particularly those not yet approved as therapeutics, may derive from animal pharmacokinetic studies with limited direct applicability to humans. The Peptide Register's peptide profiles note the delivery route and species context for cited studies where this information is available, helping readers assess the translational relevance of reported findings.

Key Considerations for Interpreting Bioavailability Data

Bioavailability is not the sole determinant of a peptide's utility; distribution, half-life, receptor binding, and clearance all contribute to pharmacological effect. A peptide with low oral bioavailability might still be clinically useful at higher doses if it is stable enough and the therapeutic window permits it, as semaglutide demonstrates. Conversely, high bioavailability does not guarantee efficacy if the peptide is rapidly cleared or poorly distributed to target tissues.

Researchers and clinicians reviewing peptide literature should always check which delivery route was used in a given study, as results from subcutaneous administration cannot be directly extrapolated to oral or nasal delivery without pharmacokinetic bridging data. This context is essential for accurate interpretation of published findings across the peptide research landscape.